<DOC>
	<DOCNO>NCT01272908</DOCNO>
	<brief_summary>This study evaluate safety effectiveness MabThera ( rituximab ) patient active rheumatoid arthritis receive methotrexate , previous current inadequate response one prior anti-TNF therapy . All patient receive MabThera 1000 mg intravenous infusion day 1 15 . After initial study phase 24 week , eligible patient may receive one re-treatment MabThera . The anticipated time study treatment 48 week .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Patients With Rheumatoid Arthritis Who Have Failed One Prior Anti-TNF Therapy ( RESET )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , 1880 year age Moderate severe active rheumatoid arthritis Inadequate response single previous current treatment antiTNF agent Methotrexate least 12 week , stable dose past 4 week Previous treatment MabThera Use antiTNF agent within past 8 week ( 4 case etanercept ) Concurrent treatment Disease Modifying AntiRheumatic Drug ( DMARD ) methotrexate Active infection , history serious chronic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>